CA Medical

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company's lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.

MOUNT VERNON, Wash. -- PreViser Corporation, announced today the release of a Web based tool, myDentalScore, that allows individuals to calculate objective numeric scores for oral disease risk and severity. The tool is available for immediate use by dentists, companies and consumers.

COSTA MESA, Calif. -- Renaissance Surgical Arts at Newport Harbor today announced that it has met or exceeded compliance with the Joint Commission's national standards for health care quality and safety, earning the Joint Commission's Gold Seal of Approval. This is the second accreditation for Renaissance, the multispecialty ambulatory surgery center opened in August 2010 with its accreditation from IMQ.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G.

BEVERLY HILLS, Calif. -- Cognitive Behavior Associates, a group practice specializing in the delivery of Cognitive-Behavior Therapy, is pleased to announce a new treatment program for individuals suffering from Irritable Bowel Syndrome - Going Well(R).

DAVIS, Calif. -- California IVF: Davis Fertility Center, Inc. proudly announces a new contract with NorthBay Healthcare, a plan administrator for Western Health Advantage insurance. This contract expands infertility treatment options for NorthBay Healthcare members as well as members of other Western Health Advantage medical groups.

DAVIS, Calif. -- California IVF: Davis Fertility Center, Inc., working in conjunction with Gene Security Network leads the field in bringing a new test to patients that combines the detection of single-gene genetic disorders with a 24 chromosome screening.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled 'Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma' at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.

PARAMUS, N.J. -- Topcon Medical Systems announced today that the mobile version of its successful EyeRoute(R) Image Management Suite is now available as a dedicated iPhone application from the Apple(R) iTunes store in North America. First presented in October 2009 at the American Academy of Ophthalmology Meeting in San Francisco, EyeRoute Mobile sets the stage for connectivity on the go.

COSTA MESA, Calif. /California Newswire/ -- Renaissance Surgical Arts at Newport Harbor, a new cutting edge outpatient surgical facility located within the Pacific Medical...

SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies' Rexin-G is the world's smallest hero. Imagine if you will, a tiny particle that can travel...

LOS ANGELES, Calif. /California Newswire/ -- In today's economy, more than ever, every dollar counts. That's why STAT Medical Consulting, Inc. announces that they...

SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies (epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G(R) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a week for 4 weeks. Treatment cycles are repeated if the patient exhibits Grade 1 or less toxicity.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G.

ENCINO, Calif. -- In December 2007, MedSort.com, a premier online personal medication list management system, launched a comprehensive personal health records system - MedSort Health(TM) - which empowers consumers and patients to take control of their health records. Since January 2007, MedSort.com has been helping patients to create and manage their medication and allergy list online.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials.

SAN DIEGO, Calif. -- Always Best Care Senior Services has expanded into the San Diego area. America's premier In-Home Care, Assisted Living Placement Service, and Personal Response Company, is proud to announce seniors in San Diego can now rely on Always Best Care Senior Services for outstanding care.

SAN MARINO, Calif. and BOSTON, Mass. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on "The Advent of Pathotropic Medicine for Cancer" at the Global Pharma R&D Summit 2007 to be held in Boston MA.

SAN FRANCISCO, Calif. -- California Kidney Cancer Foundation Executive Director, Dr. David Minor will present a review of treatments for metastatic kidney cancer as presented at the most recent American Society of Clinical Oncology Conference. The presentation will be from 3 to 5 PM on September 15, 2007 at California Pacific Medical Center, 2333 Buchanan Street, San Francisco.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world's first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour - was published in the June issue of the International Journal of Oncology.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 Dr. Hall will present the scientific principles, clinical validation, and global development status of the company's innovative tumor-targeting technology.

TEHACHAPI, Calif. -- The Tehachapi Hospital Foundation, an IRS 501(c)(3) organization, is actively seeking funds to build a new hospital in a region between Lancaster and Bakersfield, CA - Tehachapi. The present Tehachapi Hospital is unable to meet state-mandated earthquake safety requirements; the existing structure cannot be retrofitted.

REDONDO BEACH, Calif. -- DermHair Clinic, a division of FineTouch Dermatology, Inc., located in Redondo Beach, Calif., offers a unique hair-restoration procedure called "Body Hair Transplantation" (BHT) where body hair is transplanted to balding areas on the head.

SAN MARINO, Calif. -- Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy. The lead investigator of the Japanese study, Dr. Takaki Imamura, will be presenting his findings and clinical recommendations at a special medical conference to be held in Tokyo, Japan, on December 16, 2006.